Clinical Trial Site

Montreal H4N 2W2

3 studies enrolling now · 6 studies all time

What they study most

ANCA-Associated Vasculitis, Amyloidosis, Hereditary, Cerebral Amyloid Angiopathy, Early-Onset Alzheimer Disease, High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension, Transthyretin Amyloidosis

Studies at this site

• A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD — Recruiting now
• A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) — Completed
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis — Completed